Fosun Pharmaceuticals: The holding subsidiary's drugs are included in the breakthrough therapeutic drug program

Fosun Pharmaceutical (600196.SH) announced that the company's FCN-159 tablets for the treatment of Langerhans histiocytosis in children have been included in the breakthrough drug program. The new drug is a MEK1/2 selective inhibitor and is intended mainly for the treatment of advanced solid tumors, neurofibromatosis type 1, dendritic cell and histiocytic tumors, and low-grade gliomas. As of April 2025, the Group's cumulative R&D investment for this new drug at this stage is approximately RMB 0.598 billion. According to the requirements of relevant Chinese regulations, the new drug still needs to be carried out in a series of clinical studies in China and approved by the national drug review department before it can be marketed.